Command Palette

Search for a command to run...

Clinical Trials · NCT06388187

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
300
Start date
Jun 2024
Locations
25 sites, 5 countries
Primary endpoint
Relative change in body weight
View Semaglutide compound reference